REGENXBIO Inc. Stock News

ROCKVILLE, Md. , March 11, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate the following upcoming investor conferences: Leerink Partners 2024 Global Biopharma Co

Data from an early-stage study shows that treatment with REGENXBIO's (RGNX) investigational Duchenne therapy RGX-202 demonstrates early evidence of strength and motor function improvement.

Company to host webcast on Tuesday, March 5, 2024 at 8:30 a.m. EST Interim clinical data will be presented by Aravindhan Veerapandiyan, M.D.

REGENXBIO Inc. (RGNX) Q4 2023 Earnings Call Transcript

Regenxbio (RGNX) came out with a quarterly loss of $1.43 per share versus the Zacks Consensus Estimate of a loss of $1.27. This compares to loss of $1.38 per share a year ago.

ROCKVILLE, Md. , Feb. 21, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Tuesday, February 27, 2024, at 4:30 p.m.

REGENXBIO (RGNX) gains 12% on positive top-line results from the phase I/II/III study of its investigational one-time gene therapy candidate, RGX-121, to treat pediatric patients with Hunter syndrome.

Regenxbio (RGNX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength

REGENXBIO's stock has consistently underperformed, down 26% since May. The company released positive interim data from their Phase II trial for the treatment of wet age-related macular degeneration. T

REGENXBIO Inc. (NASDAQ:RGNX ) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Patrick Christmas - Chief Legal Officer Ken Mills - Chief Executive Officer Steve Pakola

ROCKVILLE, Md. , Nov. 7, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate the following upcoming investor conferences: Stifel 2023 Healthcare Conference  Firesid

Regenxbio Inc. is making progress in its pipeline, aiming to have five gene therapies in late-stage testing or approved by 2025. The company's lead candidate, ABBV-RGX-314, is being developed for the

ROCKVILLE, Md. , Nov. 1, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Wednesday, November 8, 2023, at 4:30 p.m.

ROCKVILLE, Md. , Sept. 5, 2023 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following upcoming investor conferences: Morgan Stanley 21st Annual Global Healt

REGENXBIO is a biotech company specializing in gene therapy, with a focus on addressing unmet medical needs in genetic disorders. The company's cash position decreased to $415.4 million, but it is pro